• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
How to begin treatment in chronic heart failure? * Ronnie Willenheimer
How to begin treatment in chronic heart failure? * Ronnie Willenheimer

... absolute difference, 21.6%; 95% CI 27.6 to þ4.4%; HR, 0.94; 95% CI, 0.77–1.16; non-inferiority for bisoprolol-first vs. enalapril-first, P ¼ 0.019. Thus, the intention-to-treat analysis met the pre-specified non-inferiority limits for the upper confidence interval of þ5% for absolute difference (¼re ...
File - Spirit of Healing: Alberta First Nations Conquering
File - Spirit of Healing: Alberta First Nations Conquering

... treatments for opioid dependence as just substitutions of one addictive drug for another. People on medication-assisted treatment are not considered to be addicted – addiction is pathologic use of a substance that may or may ...
article in press - MRC
article in press - MRC

Treatment Guidelines for the Pharmacological Management of Pain
Treatment Guidelines for the Pharmacological Management of Pain

... Dosing levels may need to be adjusted to prevent drug toxicity, especially drugs with active metabolites, such as morphine [7,13] (see Table 4). Pharmacologic Therapies Choosing an analgesic treatment will largely depend on the cause and intensity of pain and other individual patient factors, such a ...
Clenbuterol syrup_leaflet_engl
Clenbuterol syrup_leaflet_engl

... organism, comparable to that of anabolic drugs. Its effect is expressed in a reduction of protein degradation in muscle cells, leading to an increase in muscle bulk and muscle strength. The enhanced metabolism of masts is another Clenbuterol pharmacodynamic property. In the prescribed therapeutic do ...
2-1 Prescription (Legend) Drugs
2-1 Prescription (Legend) Drugs

... adverse effects in this phase by health professionals who are treating clients. If serious adverse effects occur, drug is recalled. Back to the drawing board! ...
Chemistry Report
Chemistry Report

... aggravated depression, and manic reaction. one patient treated with placebo (n =97) was discontinued after an attempted suicide. Most commonly observed adverse reactions in controlled trials: During treatment with Ambien CR in adults and elderly at daily doses of 12.5 mg and 6.25 mg, respectively, e ...
Powerpoint
Powerpoint

... • While we are interested in automated function prediction, we are particularly interested in how AFP techniques can be applied to the pharmaceutical sciences – this is what I will cover today ...
Shared Care Guideline
Shared Care Guideline

... take on shared care only if they are willing and able. In cases where shared care arrangements are not in place, or where problems have arisen with the agreement such that patient care may suffer, the responsibility for the prescribing and management of the patient will revert to the secondary care ...
Combination Antiretroviral Threapy for HIV Infection
Combination Antiretroviral Threapy for HIV Infection

... against AZT-resistant HIV isolates. In the study of Staszewski et al., plasma HIV-RNA level in patients receiving EFV/AZT/3TC decreased greater than in ...
Extensions to Mendel`s Law
Extensions to Mendel`s Law

... • Gene products control expression of phenotypes differently. • Mendel’s M d l’ law l off segregation ti still till applies. li • Interpretation p of p phenotype/genotype yp g yp relation is more complex. ...
rational selection of pcr-based platforms for pharmacogenomic testing
rational selection of pcr-based platforms for pharmacogenomic testing

... genotyping platform stands out as ideal and it is likely that many of the different technologies described in this article will be employed in combined studies aimed to find disease genes and novel drug targets. NEEDS TO DETECT GENETIC VARIATIONS IN CANCER CHEMOTHERAPY ...
PHAR 7633 Chapter 7 Routes of Drug Administration
PHAR 7633 Chapter 7 Routes of Drug Administration

... By-pass liver - Some (but not all) of the veins draining the rectum lead directly to the general circulation thus bypassing the liver. Therefore there may be a reduced first-pass effect. Useful - This route may be most useful for patients unable to take drugs orally or with younger children. Disadva ...
BSR/BHPR guideline for disease-modifying anti
BSR/BHPR guideline for disease-modifying anti

... (BNF) and publications from various clinical trials in the specialty literature [3–6]. The adverse effects of DMARDs as reported in research trials have limitations, as the patient characteristics are likely to be different from those in daily clinical practice. It is desirable if not necessary, to ...
Genomic Consequences of Background Effects on scalloped Mutant
Genomic Consequences of Background Effects on scalloped Mutant

... each isolated in a different genetic background. Unfortunately the consequences of the background effects are rarely explicitly addressed and thus remain a confounding effect in the analysis, and subsequent interpretation of, the phenotypes. This concern may be particularly acute for the analysis of ...
1-skeletal muscle relaxants-2014 December
1-skeletal muscle relaxants-2014 December

... Inability to bind calcium by sarcoplasmic reticulum in some patients due to genetic defect.  Ca release, intense muscle spasm, hyperthermia ...
FULL PRESCRIBING INFORMATION
FULL PRESCRIBING INFORMATION

... of the possible occurrence of diarrhea during treatment. Patients should be instructed to discontinue Amitiza and inform their physician if severe diarrhea occurs [see Adverse Reactions ...
RSPT 2217 Calculating Drug Doses
RSPT 2217 Calculating Drug Doses

... • hecto = 100 • kilo ...
Antipsychotics
Antipsychotics

... something that is not there). Formerly known as major tranquilizers and neuroleptics, antipsychotic medications are the main class of drugs used to treat people with schizophrenia. They are also used to treat people with psychosis that occurs in bipolar disorder, depression and Alzheimer’s disease. ...
Hormona del Crecimiento y Dopaje Genético
Hormona del Crecimiento y Dopaje Genético

... Gene therapy now represents a proven, although very immature and still experimental field of human medicine. ...
Muscle Relaxants
Muscle Relaxants

... Although atracurium produces few direct circulatory effects, the absence of vagal blocking activity makes the patient vulnerable to bradycardias during anaesthesia. Histamine release may occur with doses of atracurium greater than 0.6 mg/kg. Respiratory effects In standard doses, atracurium rarely c ...
SAFE Opioid Prescribing: Strategies. Assessment. Fundamentals
SAFE Opioid Prescribing: Strategies. Assessment. Fundamentals

... activities are required to disclose all financial relationships they have with any entity producing, marketing, re‐ selling, or distributing health care goods or services consumed by, or used on, patients.  Faculty are asked to use  generic names only in the discussion of therapeutic options.  If tr ...
06/06/13 - Magellan Rx Management
06/06/13 - Magellan Rx Management

... JUXTAPID™ (lomitapide mesylate) 5 mg, 10 mg and 20 mg capsule: JUXTAPID™ is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL- ...
Prescribing Information
Prescribing Information

... Avoid use during the third trimester of pregnancy because NSAIDs such as DURLAZA may cause premature closure of the fetal ductus arteriosus. Salicylate products have also been associated with alterations in maternal and neonatal hemostasis mechanisms, decreased birth weight, and with perinatal morta ...
A Rapid Instrumented Fluorescence Immunoassay for the
A Rapid Instrumented Fluorescence Immunoassay for the

... When a sample solution containing the analyte passes through the assay reagent in the micro column, the analyte displaces the tracer at the binding site of the antibody. The displacement of flourophore-labeled THC from the immobilized antibody by saliva specimens containing THC produces a fluorescen ...
< 1 ... 452 453 454 455 456 457 458 459 460 ... 1254 >

Pharmacogenomics

Pharmacogenomics (a portmanteau of pharmacology and genomics) is the study of the role of genetics in drug response. It deals with the influence of acquired and inherited genetic variation on drug response in patients by correlating gene expression or single-nucleotide polymorphisms with drug absorption, distribution, metabolism and elimination, as well as drug receptor target effects. The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both terms relate to drug response based on genetic influences, pharmacogenetics focuses on single drug-gene interactions, while pharmacogenomics encompasses a more genome-wide association approach, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response.Pharmacogenomics aims to develop rational means to optimize drug therapy, with respect to the patients' genotype, to ensure maximum efficacy with minimal adverse effects. Through the utilization of pharmacogenomics, it is hoped that drug treatments can deviate from what is dubbed as the “one-dose-fits-all” approach. It attempts to eliminate the trial-and-error method of prescribing, allowing physicians to take into consideration their patient’s genes, the functionality of these genes, and how this may affect the efficacy of the patient’s current and/or future treatments (and where applicable, provide an explanation for the failure of past treatments). Such approaches promise the advent of ""personalized medicine""; in which drugs and drug combinations are optimized for each individual's unique genetic makeup. Whether used to explain a patient’s response or lack thereof to a treatment, or act as a predictive tool, it hopes to achieve better treatment outcomes, greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions (ADRs). For patients who have lack of therapeutic response to a treatment, alternative therapies can be prescribed that would best suit their requirements. In order to provide pharmacogenomic-based recommendations for a given drug, two possible types of input can be used: genotyping or exome or whole genome sequencing. Sequencing provides many more data points, including detection of mutations that prematurely terminate the synthesized protein (early stop codon).
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report